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1 Model descriptions and baseline comparison of malaria models 
Prior to carrying out model fitting and projecting vaccine impact, we compared the four mathematical 
models in the absence of any intervention other than treatment of malaria cases. The supplementary 
methods detail the key features of each of the models, with a focus on the assumptions, outputs and case 
definitions that lead to differences between model predictions. Details of the harmonization process are 
described, and finally baseline relations between key metrics such as parasite prevalence, entomological 
inoculation rate (EIR), clinical and severe incidence and mortality are presented. 
 
1.1 Models and harmonization assumptions 
1.1.1 Models of malaria epidemiology and vaccine impact 
The models of Plasmodium falciparum malaria used in this study were developed independently by four 
modelling groups (Institute for Disease Modelling (IDM, model name EMOD DTK) 9 , GlaxoSmithKline 
Vaccines (GSK) 16, Imperial College London (Imperial)12 and Swiss Tropical and Public Health Institute 
(Swiss TPH, model name OpenMalaria18)). Box S1.1 and Table S1.1 provide a description of each of the 
models and references for the technical details. 
 
There are some differences in case definitions between the models as listed in Table S1.2 and further 
described in Box S1.2 in relation to disease definitions for Plasmodium falciparum. 
 
The structural differences between the models mean that different sources of uncertainty are captured. 
These are listed in Table S1.3. 
1.1.2 Demographics 
Demographics of simulated human populations in the models were harmonised with birth cohort and 
population sizes based on common values. For Imperial the age structure of the population was derived 
from the life table for Tanzania 2010. For OpenMalaria a similar distribution was used, although with a 
higher mortality in the first year of life. For GSK and EMOD DTK a simple geometric distribution was used 
that provided a close match to other groups. In all models the total number of simulated individuals was 
100,000 with a non-growing static population for baseline projections. 
1.1.3 Transmission settings and access to treatment  
We explored baseline parasite prevalence in 2-10 year olds (PfPR2-10) ranging from 3% to 75%. Three of 
the models are driven by EIR (EMOD DTK, Imperial and OpenMalaria) and for those models the 
corresponding EIR ranged from 0 to 512 infectious bites per person per year. However, the specific 
relationship between EIR and PfPR2-10 varied between models (see Figure S1.1). In all simulations a flat 
seasonal profile was used. All models were assumed to be in endemic equilibrium prior to introduction of 
the vaccine. 
 
We assumed 45% of clinical episodes with patent malaria were successfully treated. In the Imperial model 
this was implemented as 52% access to ACT or non-ACT treatment (26% each), with efficacies of 95% and 
75% respectively. For OpenMalaria 45% reflects access via both informal and formal care. Some aspects 
of the OpenMalaria model may be particularly sensitive to the access to care assumptions, and for this 
reason a sensitivity analysis of 15% access to effective care was carried out when characterising the 
relationship between EIR and PfPR2-10. 
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Box S1.1: Descriptions of the four malaria models 
 
GSK is a static and stochastic individual-based cohort model calibrated to reproduce the age-incidence of clinical 
malaria from the control arm of the RTS,S Phase 3 trial and age-distribution
1
. Health states of individuals in the 
cohort follow a Markov process with 5-day cycles and a time horizon of 5 years. Clinical malaria is predicted from 
parasite densities using MAP categories for low, moderate and high transmission
2
. Human infectiousness is not 
included. Vaccination is added as an additional immunity component which further reduces infection compared with 
current interventions (mainly bednet use and treatment).  The three categories of transmission considered are 
(PfPR2-10<5%, 5<=PfPR2-10<=40%, PfPR2-10>40%). Heterogeneity in exposure among individuals is included; for each 
transmission level, some individuals are almost never exposed while others have twice the mean exposure. 
Institute for Disease Modelling – EMOD DTK is a discrete, stochastic, individual-based model of malaria in either 
local or spatially distributed settings. The vector module supports closed-loop cycles of mosquito development and 
blood-feeding for multiple independent species with temperature- and rainfall-dependent larval dynamics and 
sporogony
3
. The individual infection and immunity modules track the distribution of parasites by surface-antigen type 
with both innate and antigen-specific adapted immune responses, while human infectiousness is calculated directly 
from the mechanistic dynamics of parasite densities
4
. Blood-stage immunity is acquired through cumulative exposure 
to the set of unique and cross-reactive antigens in the parasite population
6
 with heterogeneity in individual biting rates 
included. The model accounts for the combined effect of an extensive set of both vector- and human-directed 
interventions
7,8
. The relationships between transmission intensity, parasite prevalence, clinical episodes, and severe 
disease were calibrated to historical study-site data, and an ensemble of model parameterizations sampled from the 
posterior probability distribution
9
. As in that work, the present analysis uses a simplification of the vector module, 
which models transmission directly as a periodic function of force of infection. That is, in this framework the human 
infection reservoir does not modulate the transmission intensity. 
Imperial College.  The model is a stochastic, individual-based simulation of a single population of humans linked to 
a stochastic compartmental model for mosquitoes
10
. The human infection process tracks individuals through stages 
of infection, with pre-erythrocytic and blood-stage immunity incorporated to capture the changing patterns of severe 
disease, clinical diseases and asymptomatic infection with age and exposure. The vector model includes larval 
stages as well as adult female mosquitoes to capture the feedback of vector control that kills adults on the population 
dynamics
11
. Human infectiousness is related to asexual parasite dynamics and lagged to allow for development of 
gametocytes. Multiple vector species and heterogeneity in exposure is included. The model has been extensively 
fitted to data on the relationship between the entomological inoculation rate (EIR) and parasite prevalence, clinical 
disease, severe disease and deaths using Bayesian methods
12,13
. The model captures the combined effect of 
multiple interventions, including first-line treatment, LLINs and the RTS,S vaccine. 
Swiss TPH – OpenMalaria is a stochastic, individual-based, single location simulation model of malaria in humans
14
 
linked to a deterministic models of malaria in mosquitoes
15
. The simulation model includes sub-models of infection of 
humans
17
, blood-stage parasite densities
19
, infectiousness to mosquitoes as a lagged function of asexual parasite 
density
20
, incidence of morbidity including severe and hospitalisation
5,21
 and mortality
5
. Pre-erythrocytic and blood-
stage immunity comprise separate sub-models, with blood-stage immunity predominating as infection-blocking 
immunity occurs only in those with very high cumulative exposure
19
. An ensemble of 14 model variants with varying 
assumptions is available
18
. These models include different assumptions for decay of natural immunity, greater within-
host variability between infection and entomological exposure, heterogeneity in transmission and heterogeneity in 
susceptibility to co-morbidities. In this work only six of the ensemble models were used and transmission is modelled 
through periodically varying vectorial capacity.  
 
1.2 Relationships with prevalence 
1.2.1 EIR-parasite prevalence relationships 
The predicted relationship between EIR and PfPR2-10 (Figure S1.1) differs slightly between the models, with 
variation consistent with the data used to inform them. For OpenMalaria and EMOD DTK the relationship is 
highly dependent on the level of case management, which has implications for the clinical disease 
incidence relationships. Higher treatment at a given EIR results in lower PfPR2-10 and lower clinical 
disease22. This is due to the following: 1) parasite prevalence is indirectly related to malaria transmission 
because of effects of naturally acquired immunity and of heterogeneity in transmission rates and; 2) the 
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amount of treatment in the population truncates infections. If access to effective treatment is high, then 
prevalence may remain relatively low, even at high transmission levels and this also affects the 
relationships with incidence22. 
1.2.2 Prevalence-incidence relationships 
Baseline relationships were established between PfPR2-10 and clinical incidence (Figure S1.2), severe 
incidence (total) (Figure S1.3), hospitalised cases (Figure S1.4), and mortality (Figure S1.5), each broken 
down into discrete age groups. For the OpenMalaria model extrapolations of the prevalence-incidence 
relationship are subject to a high degree of uncertainty at very high PfPR2-10 (>70%) and so results for 
these PfPR2-10 levels are not shown. 
 
EMOD, Imperial and OpenMalaria all predict a decrease in incidence for ages greater than five years old at 
high PfPR2-10 (due to higher natural immunity from higher exposure earlier in life compared to low PfPR2-10 
settings). This decrease is larger for OpenMalaria as incidence is higher overall owing to differences in 
case-definitions, model immunity assumptions, and the data used to parameterise the model. For 
hospitalised cases there is agreement between OpenMalaria and Imperial. 
 
All models predict the majority of deaths to occur in the 0-5 year old age range at high transmission. At low 
transmission all models predict fewer deaths distributed over a broader age range. Differences between the 
models for mortality relationships can be attributed to the data used to parameterise them and the definition 
of a malaria death, as well as differences in model structure. In OpenMalaria deaths include those directly 
attributable to the disease and those caused by co-morbidities; in the other three models mortality 
represents direct malaria deaths (albeit potentially including a small fraction of deaths from other causes 
due to parameterisation against imprecise verbal autopsy data). 
1.3 Age-incidence relationships 
Acquisition of immunity and the speed with which this is acquired due to infection changes the observed 
incidence with age and transmission intensity23. In low PfPR2-10 incidence is seen in older ages compared to 
higher PfPR2-10 settings (Figures S1.7-S1.9). This is captured in all of the models, with incidence varying 
with age and transmission as a result of immunity acquisition and assumptions, with decreasing clinical 
incidence with age for higher transmission sites (Figure S1.6). The magnitude of clinical incidence differs 
across the models due to different case-definitions with two of the models (GSK and Imperial) modelling 
only one possible clinical case per infection. Total severe malaria by age and PfPR2-10 for three of the 
models is shown in Figure S1.7, hospitalised cases Figure S1.8, and malaria-related deaths in Figure S1.9, 
broken down by transmission intensity (defined in terms of PfPR2-10) and model. For the OpenMalaria 
model both direct deaths (deaths from malaria) and total deaths (including deaths from comorbidities 
associated with malaria) are shown. 
1.4 Epidemiological relationships to aid interpretation of impact of malaria 
interventions across the models  
The key epidemiological relationships presented in this model comparison aid in later interpretation of 
differences between model predictions of impact of malaria interventions such RTS,S. The age-incidence 
and prevalence-incidence relationships indicate the burden by age-group that it is possible to avert at a 
particular PfPR2-10 by an intervention. In particular, the difference in case definitions and the number of 
cases per infection between the models influences not just the burden but also the differences in predicted 
impact on clinical cases of any intervention at higher prevalence.  
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Box S1.2: Disease definitions for P.falciparum malaria 
Infection with Plasmodium falciparum can lead to a number of different health outcomes, with a general trend 
towards decreasing pathology following the gradual acquisition of immunity by exposure and age. However, immunity 
is partial and hence episodes can occur across all age groups with asymptomatic carriage of parasite common in 
older children and adults. Young children are at risk of severe disease, the life-threatening form of malaria, which 
typically presents as either severe anaemia or cerebral malaria. There is no single clear definition of severe disease 
but in general this form of disease requires hospitalisation. Severe disease may onset very rapidly or can develop as 
a consequence of untreated clinical disease. Clinical disease (also referred to as mild or uncomplicated) is 
characterised by bouts of recurrent fever due to the cyclical burst of parasites during blood-stage infection. This is 
most often defined in research studies and trials on the basis of measured fever plus parasite density in the blood 
over some threshold, although again there is no single standard definition. Artemisinin combination therapies (ACTs) 
are indicated for treatment of clinical malaria, with hospitalisation only required in the case of additional 
complications. Asymptomatic infection is defined as the presence of parasites in the blood with no associated clinical 
symptoms. This can either be “detectable” (based on common diagnostics, including microscopy and rapid diagnostic 
tests) or “undetectable” (or sub-patent) which refers to low density infections detectable only using PCR methods. 
Across the four models, the definition of clinical malaria is similar but the number of uncomplicated clinical cases 
that can occur per infection differs (for GSK and Imperial only one clinical case per infection can occur, whereas for 
EMOD DTK and OpenMalaria multiple episodes can occur). For severe malaria, three models (EMOD DTK, GSK, 
and OpenMalaria) provide predictions of total severe malaria cases, including those receiving in-patient treatment 
and those that would be classified as severe in the community. The incidence of hospitalised malaria cases is 
provided by all groups. In the EMOD DTK and OpenMalaria models, these are a subset of severe malaria cases; for 
GSK some hospitalised cases may also be clinical; for Imperial all symptomatic cases (both clinical and severe) are 
counted among the clinical, and hospitalised malaria is defined from studies that may include cases who do not meet 
a strict definition of severe malaria.  
Mortality associated with malaria is predicted by all models, however there are differences by model, reflecting the 
wider uncertainty in the mortality attributable to malaria. The OpenMalaria model explicitly records total malaria 
deaths which includes those associated with co-morbidities, either inside or outside of hospital, and direct malaria 
deaths that are directly attributable to malaria. Indirect deaths are deaths that would be averted by eliminating 
malaria, but where malaria is not assigned as the main cause of death. These are mainly associated with co-
morbidities, which would be expected to decrease with improved treatment of other diseases. In general predictions 
from OpenMalaria in this report are for all deaths. The Imperial model is fitted to data taken from verbal autopsy (VA). 
Thus, while this model does not include any explicit parameterisation of deaths due to co-morbidities, some indirect 
deaths are implicit in fitting to VA as VAs have issues of sensitivity and specificity. In the GSK model malaria mortality 
is estimated as a fixed percentage of severe cases (case-fatality risk), with values for hospitalised and non-
hospitalised severe cases obtained from published literature
1
. Deaths with co-morbidities are included by GSK as 
these are included in the case definition of severe malaria. In the EMOD DTK analysis, malaria mortality was 
estimated as a fraction of severe cases, following the methodology outlined used previous by OpenMalaria
5
. For 
malaria deaths, given the uncertainty and variability in data used to parameterise the models, it is appropriate to 
consider the estimates across the models as a representation of uncertainty in predictions. 
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Figure S1.1 Relationship between EIR and PfPR2-10 in three models. Solid lines show medians and shaded 
regions show 95% credible intervals. EIR denotes the entomological inoculation rate.  
 
 
Figure S1.2 Yearly incidence of clinical (uncomplicated) malaria as a function of PfPR2-10 displayed by model 
and age group.  Clinical incidence is presented in terms of the yearly number of events per person. 
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Figure S1.3 Yearly incidence of total severe malaria as a function of PfPR2-10, displayed by model and age 
group. Incidence is presented in terms of the yearly number of events in a population of 1000 individuals. (Imperial do 
not estimated severe cases) 
 
Figure S1.4 Yearly incidence of total hospitalised malaria as a function of PfPR2-10, displayed by model and 
age group. Incidence is presented in terms of the yearly number of events in a population of 1000 individuals. 
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Figure S1.5 Yearly number of malaria-related deaths as a function of PfPR2-10, displayed by model and age 
group. Malaria mortality incidence is presented in terms of the yearly number of deaths in a population of 1000 
individuals. For the OpenMalaria model both deaths directly attributed to malaria (dotted curve) and all deaths 
associated with malaria (including both deaths directly attributable to malaria and those associated with comorbidities) 
are shown (full line).  See Box S1.2 for definitions of deaths attributable to malaria in the models. 
 
Figure S1.6 Yearly incidence of clinical malaria as a function of age, displayed by transmission intensity 
(PfPR2-10) and model. Clinical incidence is presented in terms of the yearly number of events per person. 
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Figure S1.7   Yearly incidence of total severe malaria as a function of age, displayed by transmission intensity 
(PfPR2-10) and model. Incidence is presented in terms of the yearly number of events in a population of 1000 
individuals. (Imperial only estimate hospitalised severe cases and so are not shown here). 
 
Figure S1.8 Yearly incidence of total hospitalised malaria as a function of age, displayed by transmission 
intensity (PfPR2-10) and model. Incidence is presented in terms of the yearly number of events in a population of 
1000 individuals. 
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Figure S1.9 Yearly incidence of malaria-related deaths as a function of age, displayed by transmission 
intensity (PfPR2-10) and model. Malaria mortality incidence is presented in terms of the yearly number of deaths in a 
population of 1000 individuals. The dashed estimates for OpenMalaria represent direct malaria deaths, and the solid 
all malaria deaths (including those attributable to co-morbidities). 
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Table S1.1. Detailed descriptions of the models 
 GSK Imperial College Institute for Disease Modelling – 
EMOD DTK 
Swiss TPH – OpenMalaria 
Key representative publications Conference presentations
16,24
  
 
Journal articles
10,12,13,25
  Journal articles
3,4,6-9
 
26
 Journal articles
14,17,21
 
5,15,18-20,27
  
Accessibility 
 
A deterministic version of the model 
has been developed in MS Excel 
which can be shared upon request 
 
Interface to published model allows 
the user to run the model on their 
PC. Incorporates estimated 
prevalence, vector species, 
seasonality, ITN coverage and 
treatment at ADMIN1 level that the 
user can change. Current version 
released as part of the Elimination 
Scenario Planning Tool (WHO 
GMP) in April 2014. 
https://www1.imperial.ac.uk/malaria
modelling/toolsdata/ 
Latest Windows release of EMOD 
malaria model and documentation 
can be downloaded from 
idmod.org/software 
Code is open source. Runs on 
Windows, Linux and Mac. Full 
documentation is found at 
https://github.com/SwissTPH/open
malaria/wiki 
PATH Malaria Vaccine Initiative has 
a number of pre-populated 
simulations of one of the 
OpenMalaria models with a simple 
interface and supply, demand, cost 
information
28
 
 
Seasonality No Yes Yes Yes 
Heterogeneity in exposure Yes Yes Yes Yes 
Blood-stage parasite densities 
modelled  
No No Yes Yes 
Parameterization for clinical 
incidence 
Fitted to RTS,S Phase III trial Fitted to cross-sectional age-
incidence data from 23 sites in 
Africa capturing differences 
between active and passive case 
detection 
12
 
Calibrations to 4 sites for 
parasitaemia (Nigeria, Tanzania), 
Dielmo and Ndiop (Senegal) 
29
 for 
age-incidence of clinical malaria 
Calibration for age-incidence of 
clinical malaria for Dielmo and 
Ndiop in Senegal
29
, and Idete, 
Tanzania
30
  
Parameterization for severe 
disease and mortality incidence 
Fitted to Phase III trial for severity 
and overall mortality using case 
fatality rate (CFR) from WHO 
report
31
 
Severe disease model
13
 fitted to 
data from northern Tanzania
32
 and 
to severe disease vs. prevalence 
relationship from data of multiple 
sites
33
. Mortality due to malaria is 
based on Africa-wide data from 
verbal autopsy and parasite 
prevalence
34
.  
Age incidence of severe malaria 
fitted to 5 sites in The Gambia and 
Kenya
35
. Proportion of severe 
disease from anemia and cerebral 
malaria
36
 CFR was normalized to 
match WHO death estimates. 
Severe disease and mortality 
model
5
 fitted to all-cause and 
cause-specific age-specific mortality 
from pre-LLIN and pre-ACT era, to 
hospitalisation rates by prevalence 
for multiple sites
33
 and to age 
incidence of hospitalized severe 
malaria
35
 (with age-specific CFR 
based on Tanzanian data
32
) 
Vaccines interventions Pre-erythrocytic vaccines Transmission blocking, pre-
erythrocytic and combinations 
Transmission blocking vaccines, 
blood stage vaccines, pre-
erythrocytic and combinations 
Transmission blocking vaccines, 
blood stage vaccines, pre-
erythrocytic and combinations 
Pre-erythrocytic vaccine effect in 
the model 
Proportionate reduction in force of 
infection, exponential and bi-phasic 
Proportionate reduction in force of 
infection. Vaccine efficacy decays 
Proportionate reduction in force of 
infection, exponential decay. 
Proportionate reduction in force of 
infection assuming beta distributed 
16 
 
 GSK Imperial College Institute for Disease Modelling – 
EMOD DTK 
Swiss TPH – OpenMalaria 
decay using exponential or biphasic 
decay, or using an antibody-based 
function informed by Phase II/III 
studies.  
variation in efficacy. Various 
different assumptions concerning 
vaccine efficacy and its decay have 
been modeled, including 
exponential and biphasic-like 
(implemented via Weibull decay 
function) 
Vector control Interventions Assumes that parasite prevalence 
levels represents prevalence under 
current levels vector control 
interventions without modelling 
them explicitly 
LLIN, IRS, Larval control (larviciding 
& pupaciding)  
Novel interventions - GM 
mosquitoes, Ivermectin, Attractive 
Toxic Sugar Baits 
LLIN, IRS, Larviciding-- effect 
depends on vector species-specific 
feeding behaviors Novel vector-
control interventions: ivermectin, 
GM mosquitoes, individual and 
spatial repellents, oviposition traps, 
sugar-baited traps, etc. 
LLIN, IRS, Larviciding, repellents 
and screening, zooprophylaxis, 
odour-baited traps, sugar-baited 
traps -- effect depends on vector 
species-specific feeding behaviors. 
Model includes loss of insecticide 
and development of holes in LLINs. 
Treatment interventions Treatment of clinical disease and 
severe disease. 
Treatment of clinical disease and 
severe disease, by specified drug 
and diagnostic. 
Mass screen and treat, IPTi, 
IPTc/SMC and IPTp/IST for 
separate pregnancy model 
Drugs (routine access, mass 
administration, age- and risk-group 
targeting, diagnostic-guided 
administration) 
Treatment of clinical disease and 
severe disease, by specified drug, 
facility level and diagnostic. 
Mass screen and treat, MDA, IPTi, 
IPTc/SMC. Model allows for drug 
resistance. 
Spatial dynamic model No Capacity to run full spatial model, 
including spatial interactions, 
although for this exercise model 
was run independently at ADMIN1 
level and aggregated, thereby 
capturing spatial heterogeneity but 
not spatial interactions. 
Yes No 
Predictions for country or 
geographic area 
Yes Yes (see above) Yes Yes. Based on MAP
37
 prevalence, 
population and access to effective 
treatment by geographic area
38
  
Super-infections No New infection takes priority over 
existing infection 
Superinfections with each infection 
having its own antigenic repertoire 
(possibly partially overlapping) 
Superinfections occur with summed 
parasite densities 
 GSK Imperial College Institute for Disease Modelling – 
EMOD DTK 
Swiss TPH – OpenMalaria 
Exposure Age dependent exposure, restricted 
to 0-10y. Susceptibility to infection 
increases with age 
Exposure varies both by age and 
between individuals. 
Configurable age-dependent 
exposure functions. 
Age dependent exposure with non-
linear function describing 
relationship between exposure and 
infection, with exposure rate varying 
17 
 
 GSK Imperial College Institute for Disease Modelling – 
EMOD DTK 
Swiss TPH – OpenMalaria 
stochastically dependent on body 
surface area
17
 . 
Infection-blocking immunity Infection-blocking immunity and 
immunity against severe malaria 
develop with the number of previous 
infections 
Infection blocking immunity 
develops with exposure and age. 
Minimal natural pre-erythrocytic 
immunity is attained through 
sustained exposure to infectious 
bites.  
Infection-blocking immunity occurs 
only in those with very high 
cumulative exposure
17
 
Blood stage infections and 
immunity 
Blood stage immunity is acquired 
through exposure to blood stage 
infections, increasing with number 
of infections. Immunity acts against 
clinical and severe disease, with 
immunity to severe acquired faster 
than clinical disease. 
Blood stage immunity develops with 
exposure and age, reducing both 
detectability of infection and 
onwards infectiousness. 
Blood-stage immunity is acquired 
through the cumulative exposure to 
different malaria infections with 
varying but partly overlapping 
antigenic repertoires 
Blood stage immunity develops with 
cumulative exposure to parasite 
densities and malaria infections. 
Effect of blood-stage immunity is to 
reduce parasite density. Conditional 
distributions of parasite densities 
are log-normal
19
 
Duration of infection Fixed duration of infection Duration of infection is "Erlang-like" 
distribution (convolution of 
exponential distributions) 
Duration of infection driven by 
strength of hyper-immune response 
to discrete repertoire of antigens 
presented by each clonal infection.. 
Duration of infection is log normal 
Clinical disease and history of 
exposure 
Immunity against clinical disease 
increases based on the number of 
previous infections (calibrated) 
3 levels of risks of infection 
considered based on parasite 
prevalence 
39
 
A proportion of infected individuals 
go on to develop clinical disease. 
Immunity to clinical disease 
develops with exposure and age, 
and also has a maternally acquired 
component. 
Clinical disease is triggered by pro-
inflammatory cytokines in response 
to parasite density passing through 
a configurable pyrogenic threshold, 
down-regulated to specific antibody 
production. 
Clinical diseases is triggered by 
parasite densities and individual 
pyrogenic threshold. Pyrogenic 
threshold is dependent on history of 
exposure, with cumulative exposure 
characterised by diversity of 
previous infections and cumulative 
parasite density
21
. 
Decay of natural immunity No decay of naturally acquired 
immunity (calibrated) 
Exponential decay of naturally 
acquired immunity 
Capacity for antibody production to 
specific parasite antigens decays to 
memory levels upon clearing an 
infection  
Original model included no decay of 
natural immunity. Three model 
variants in the ensemble include 
different functional forms for decay 
of immunity
18
. 
Infectiousness and gametocyte 
models 
Human infectiousness not included, 
hence no change in transmission 
following intervention 
Human infectiousness to mosquitos 
is a weighted sum over the different 
human infectious states. A time lag 
between asexual parasitemia and 
infectious gametocytemia accounts 
for the lag in gametocyte 
development. 
Probability of infecting mosquito is 
sigmoidal function of gametocyte 
density. Inflammatory immune 
response limits infectiousness of 
individuals 
Infectiousness depends on lagged 
asexual parasite densities and on 
presence of gametocytes in blood 
meal which is a stochastic function 
of gametocyte density. Both male 
and female gametocytes must be 
present to infect mosquito
20
.  
Entomological models  No Vector control interventions include 
significant additional feedback of 
Separate mosquito populations for 
each species. Mosquito feeding 
Entomological model includes 
different species (or types) of 
18 
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EMOD DTK 
Swiss TPH – OpenMalaria 
killing of adult mosquitoes on 
mosquito dynamics. 
behavior (e.g. fraction of attempted 
indoor feeds) and larval-habitat 
preference are currently constant 
parameters for each species.  
mosquitoes with explicit infection 
stages and heterogeneous survival 
probabilities depending on host, 
intervention and mosquito. Vector 
control interventions include 
feedback of killing of adult 
mosquitoes on mosquito population 
dynamics
15,40
. Effects of resistance 
to vector control on mosquito 
survival and infection included in the 
entomological model 
Outcomes from the models relevant for vaccine impact and cost-effectiveness 
Transmission related inputs and 
outcomes  
Input: Prevalence Input: EIR 
Output: Prevalence of infection by 
microscopy and PCR by specified 
age group 
Input: EIR 
Output: Prevalence of infection by 
specified age group 
Input: EIR 
Output: Prevalence of infection by 
microscopy and PCR specified age 
group 
Outcomes: Disease related (see 
Table S1.2 for case definitions) 
Clinical cases 
All severe cases and hospitalized 
Deaths due to malara 
DALY 
Cost-effectiveness 
Clinical cases 
Hospitalisation due to malaria 
Deaths due to malara 
DALYs 
Cost-effectiveness 
Clinical cases 
Severe and hospitalized cases 
DALYs (based on severe disease 
calibration above, with 
harmonization around total death 
numbers) 
Cost-effectiveness 
Clinical cases 
All severe cases and hospitalized 
Deaths (both directly attributable to 
malaria and indirect associated with 
co-morbidities) 
DALYs (based on direct deaths or 
all deaths) 
Cost-effectiveness 
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Table S1.2 Malaria case definitions in the four models 
Malaria case definitions GSK Imperial EMOD DTK OpenMalaria 
Clinical uncomplicated malaria  Based on secondary case definition 
1 of the Phase 3 trial: children 
presenting with fever and parasite 
density >0/μL   
The definition of uncomplicated 
malaria in the model is governed by 
the data that the model was fitted to. 
The model is calibrated to the 
incidence that is detected via daily 
active case detection. Case 
definitions in the input data fell into 
two groups: malaria symptoms plus 
any parasitaemia, or malaria 
symptoms plus a parasite density 
above a non-zero threshold. In the 
model, only one episode of clinical 
disease can occur with each new 
infection. 
The definition of a clinical malarial 
incident is configurable in the 
EMOD model; for this study, a 
clinical incident begins when an 
individual’s body temperature is 
raised by 1.5°C. Parasite density 
alone does not trigger a clinical 
incident, though temperature and 
parasite density are implicitly linked 
through the innate immune 
response. The clinical incident 
continues until the fever remains 
below 0.5°C for two weeks; this 
refractory period prevents the 
multiple recrudescent fever events 
typical to malaria from being 
recorded as multiple independent 
clinical incidents. 
9 
An episode of uncomplicated 
malaria is a period during which an 
individual has symptoms caused by 
malaria parasites present at the 
time of illness, where the symptoms 
do not qualify as severe 
malaria.  Uncomplicated cases are 
triggered by parasite densities over 
a pyrogenic threshold that is 
immunity dependent. The maximum 
length of the period of an episode is 
generally set to 30 days in the 
model and illness recurring within 
this period counts as the same 
episode.  Illness recurring over a 
longer duration than this is counted 
as more than one episode.   An 
illness caused by a pathogen other 
than malaria does not count as a 
malaria episode even if there is 
incidental parasitemia. 
Severe Based on secondary definition 1 
from Phase 3 trial: parasite density 
of >5,000/μL  and with one or more 
marker of severity (not excluding the 
presence of co-morbidities) 
 
The age patterns of severe malaria 
incidence were fitted using data 
from Reyburn 
32
and Marsh
33
. 
The overall incidence is calibrated 
to the study of Marsh and Snow, 
where the definition is hospitalised 
cases with malaria “parasitaemia 
and no other detectable cause for 
the clinical presentation”. 
An individual’s current state is 
mapped onto three probabilities of 
diagnosis of severe malaria due to 
three underlying causes. An 
individual’s current RBC count sets 
a probability of diagnosis due to 
anaemia and associated 
presentations, their current body 
temperature acts as a proxy for 
presentation of severe cerebral 
malaria, and their current 
parasitaemia level acts as a catch-
all proxy for other complications 
(e.g., respiratory involvement). 
Similar protections to those 
described above regarding clinical 
incidents are in place to prevent a 
Severe malaria is a potentially life-
threatening disease, diagnosable by 
clinical or laboratory evidence of 
vital organ dysfunction, requiring in-
patient care
41
. An episode of severe 
malaria is a period during which an 
individual has symptoms, qualifying 
as severe malaria, caused by 
malaria parasites present at the 
time of illness.  As with 
uncomplicated malaria, the 
maximum duration of an episode is 
set to 30 days: illness recurring over 
a longer duration than this is 
counted as more than one episode. 
20 
 
single severe presentation from 
being recorded as multiple 
incidents. 
9
 
Hospitalised malaria Malaria hospitalizations case 
definition 1 from Phase 3 trial: A 
medical hospitalization with 
confirmed parasite density 
>5,000/μL   
 Hospitalised malaria is the only 
severe malaria output (see above). 
A hospitalized case refers to an 
individual with severe malaria that 
has been admitted for in-patient 
treatment. 
Malaria hospitalisations are severe 
malaria episodes simulated as 
receiving in-patient care.   
Malaria mortality Malaria deaths are counted as a 
proportion of hospitalized severe 
malaria cases and community 
severe malaria cases 
A proportion of severe cases are 
assumed to result in mortality in 
hospital, and a further scaling factor 
is used to extrapolate this result to 
total (inside or outside of hospital) 
deaths.  
The EMOD model counts deaths 
that result directly from severe 
cases of malaria and in its current 
configuration does not account for 
mortality resulting from 
uncomplicated cases and/or 
comorbidity. Deaths in all settings 
(both hospital and community) are 
included. 
Direct malaria deaths are severe 
malaria episodes that result in 
death. 
Indirect malaria deaths are deaths 
that occur because of malaria 
infection but that do not satisfy the 
definition of direct malaria 
deaths.  These comprise neonatal 
deaths secondary to malaria in 
pregnancy, and deaths resulting 
from interactions between 
pathogens where malaria plays an 
essential role, but the terminal 
illness does not satisfy the definition 
of severe malaria. 
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Table S1.3 Summary of variability represented in predictions from each model group in baseline predictions  
Outputs GSK Imperial EMOD DTK OpenMalaria 
Baseline predictions 
including vaccine impact by 
transmission levels  
Stochastic uncertainty 
Uncertainty in immunity 
acquisition 
Heterogeneity of exposure 
 
Minimal stochastic variability. 
Uncertainty in immunity 
acquisition parameters (values 
drawn from posterior distribution 
given previous model fits). 
Stochastic uncertainty 
100 draws samples from a 12-
dimensional parameter space 
spanning high-likelihood fits to 
clinical and severe malaria 
incidence, as described in 
McCarthy
9
. 
Uncertainty due to access to 
treatment is currently only 
demonstrated in the EIR-to-
prevalence relationship. 
Stochastic uncertainty 
Model structural uncertainty 
limited to 6 models from model 
ensemble
18
 (Uncertainty due to 
access to treatment not 
currently shown in vaccine 
impact predictions, however 
shown in the EIR to prevalence 
relationship) 
Vaccine impact for best-fit 
vaccine efficacy profiles in 
representative transmission 
levels  
Same as for baseline 
Vaccine efficacy uncertainty 
Same sources of variability as 
for baseline, plus uncertainty in 
vaccine-specific parameters 
(values drawn from posterior 
distribution given fits to Phase 
III trial data). 
The above sources plus 
heterogeneity of exposure 
Same sources or variability as 
for baseline. 
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2 Supplementary methods and results: vaccine properties 
determined from Phase III clinical data 
 
Each of the models in this study was fitted independently to data from the long-term (32+ months) follow up 
of the Phase III clinical trial of RTS,S/AS01 in 11 sites. Both OpenMalaria and EMOD DTK used pooled 3-
monthly incidence data from the intention-to-treat (ITT) population under the primary case definition. GSK 
used pooled 3-monthly incidence data from the ITT population under the secondary case definition. 
Imperial used individual-level data on incidence and antibody titres from the according-to-protocol (ATP) 
population under the primary case definition. The methodologies used to fit each of the models, along with 
model fits to each of the 11 trial sites, are detailed below.  
2.1 Summary estimates of the vaccine efficacy against infection and duration of 
response using Phase 3 clinical trial data 
Estimates of the initial efficacy against infection of the RTS,S/AS01 vaccine and its waning over time are 
shown by model in Table S2.1 and Figure S2.1. Despite differences in fitting approaches and transmission 
models used to parameterise the RTS,S efficacy profile, all four groups estimate a high initial post 3rd dose 
efficacy against infection (>75% Table S2.1) in the 5-17 month cohort. The estimated waning of efficacy 
during the first 12 months post 3rd dose is similar for all 4 groups. However, there is a divergence in the 
waning profile past one year after the 3rd dose: EMOD DTK and OpenMalaria suggest a more rapid decay 
than Imperial and GSK predictions.  
 
For the 4th dose both Imperial and EMOD DTK estimate a higher initial efficacy and a slower waning of the 
vaccine than OpenMalaria and GSK. Both EMOD DTK and GSK assumed single exponential profiles for 
decay of the 4th dose efficacy, with EMOD DTK fitting a high initial response and faster decay whilst GSK fit 
a lower initial response and slower decay. OpenMalaria a priori assumed the waning profile (decay shape 
and rate of decay) for the 4th dose is the same as that following the initial 3 doses, hence their estimates 
are heavily weighted by data from the initial 18 months of follow-up in which there are more observations. 
Imperial estimate the decay to be slower than the initial decay as a consequence of a different ratio of the 
short-lived and long-lived components of the antibody responses. While the EMOD DTK model does not 
provide a mechanistic reason for slower decay, they also estimate a slightly longer half-life for the waning 
of the 4th dose. 
 
There are two potential reasons for divergence in the waning profile. Firstly, the cohort of children enrolled 
in the study arms that received their first RTS,S dose between 5 and 17 months of age is split into the 
booster (4-dose) and no booster (3-dose) arms 18 months post dose 3, resulting in a 50% decrease in 
statistical power. The follow-up also extends only to 32 months (although the last category includes follow-
up in some individuals up to 48 months). There is less power to estimate the second phase of the waning 
profile. Secondly, the groups made different parametric assumptions for the waning profiles (Table S2.1).  
 
It is important to note that a comparison of estimated initial efficacy and waning profiles should be 
considered in conjunction with the corresponding model-dependent translation from efficacy against 
infection to efficacy against clinical disease. Figures (S2.2-S2.9) show the predicted efficacy against clinical 
disease from each model in each of the 11 trial sites using their respective best estimates of the efficacy 
against infection profile. For all models, the predicted efficacy against clinical malaria falls within the 
confidence intervals of the trial data. 
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Table S2.1 Description of best-fit profile of vaccine efficacy against infection by model group from analysis of the Phase III data  
 5-17 month cohort 
initial efficacy against 
infection (at third 
dose) 
5-17 month cohort decay of efficacy 
against infection 
5-17 month cohort with 
4
th
 dose initial efficacy 
against infection at 4
th
 
dose 
5-17 month cohort decay of efficacy 
against infection for 4th dose 
GSK 83.5% (95% CrI: 57.9-
91.2) 
Bi-phasic exponential decay 
1
st
 phase: 10.3 months half life 
2
nd
 phase: 16.3 years half-life 
Switch between phase occurs at 1.2y 
after dose 3 
53.1% Exponential decay with half-life of 3.7y 
EMOD DTK 80% 13.5 months (single exponential) 40% 15 months (single exponential) 
Imperial 75.2% (95% CrI: 71.0%, 
78.9%) 
Determined by decay of antibody titres 
as follows: 
  
Half-life of short-lived antibodies: 45 
(95% CrI: 42, 48) days 
Half-life of long-lived antibodies: 591 
(95% CrI: 557, 632) days 
Proportion of short-lived antibodies 0.88 
(95% CrI: 0.87, 0.89) 
67.5% (95% CrI: 63.9%, 
71.2%) 
Determined by decay of antibody titres 
as follows: 
  
Half-life of short-lived antibodies: 44 
(95% CrI: 42, 48) days 
Half-life of long-lived antibodies: 591 
(95% CrI: 557, 632) days 
Proportion of short-lived antibodies 0.70 
(95% CrI: 0.68, 0.72) 
 
OpenMalaria 91.1% (95% CrI. 74.5-
99.7%) 
 
Estimated half-life 7.32 months (95% 
CrI. 6-9.7 months) 
Decay shape bi-phasic-like, described 
by Weibull decay shape parameter 0.69 
(95% CrI 0.54-0.9) 
49% (95% CrI 32-68.6%) 
 
As per first 3 doses 
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Figure S2.1 Predicted best fit RTS,S efficacy against infection profiles after the third dose of the primary 
course, as estimated from Phase III data in children receiving their first dose between 5 and 17 months.  
Colours indicate groups (green EMOD DTK, orange GSK, blue Imperial and purple OpenMalaria) and 
panels the use of an 4th dose at 27 months of age (left panel without 4th dose, right panel with a 4th dose). 
Note that efficacy against infection translates differently into clinical efficacy for the four models (compare 
Figures S2.2 to S2.9 for the respective model fit to clinical disease data). 
2.1.1 GSK Summary of methods and resulting vaccine properties 
RTS,S efficacy profile (defined by the initial efficacy against infection and decay over time) was estimated 
using simultaneously (1) clinical efficacies by 3-monthly follow-up periods in the intention-to-treat (ITT) 
cohort based on the secondary case definition (parasite density of >0 and presence of fever) and (2) 
efficacies against severe malaria based on secondary case definition (presence of a marker of malaria 
severity and including co-morbidities) over the follow-up periods 3-8M, 9-14M, 15-20M, 21-32M and 33M-
SE. Efficacies per clinical site were pooled into 3 transmission categories using definitions consistent with 
the Malaria Atlas Project (MAP). Low intensity is defined as parasite prevalence (PfPR2-10) ≤5%, moderate 
intensity as PfPR2-105–40%, and high intensity as PfPR2-10>40%. This definition is also consistent with the 
country-level distribution of children into each transmission category provided by MAP. 
 
The RTS,S vaccine efficacy profile was determined by least-square procedure based on the minimization of 
a distance function summing squares of errors and weighing each data point by the corresponding 95% 
confidence interval widths. 
 
Two different decay shapes were tested: single exponential or bi-phasic exponential. The half-life 
parameter of each exponential was estimated simultaneously with efficacy. For the bi-phasic decay, the 
time point for switching between exponentials is the fourth parameter estimated. No additional efficacy was 
considered against severe malaria or mortality. Bi-phasic decay was used in the final model as it better 
fitted trial data. 
 
For the 4th dose efficacy and decay, clinical efficacies of 3-monthly periods of the ITT cohort were used. A 
single exponential decay was assumed. The same least square procedure was applied to determine the 
additional efficacy against infection at the time of 4th dose and half-life. 
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Figure S2.2 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort using best-fitted vaccine profile from GSK  
 
Figure S2.3 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort with boost (4
th
 dose) using best-fitted vaccine profile from GSK  
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2.1.2 EMOD DTK Summary of methods and resulting vaccine properties 
 
EMOD DTK identified the best-fitting properties for the 3-dose and 4-dose vaccine administrations using a 
three-step procedure as outlined below. Where mentioned clinical incidence or clinical counts refers to the 
three-month aggregated intention-to-treat dataset. 
 
Step 1: Establishing effective EIRs for each of the RTS,S trial sites by fitting the clinical incidence in the 
control arm. Approximate seasonality profiles, or rather normalized seasonality “shapes”, for each site were 
generated using trial data of clinical incidence as a function of month of the year. We accounted for the 
distribution of months of the year in which vaccines were administered in each site, also based on trial 
records, to weight the time-shifted seasonality profiles into an aggregated normalized seasonality curve. 
We then fit a multiplier, an effective annual EIR, to the clinical incidence data by minimizing the difference 
between case counts in the trial and in simulations; here, ‘effective’ refers to the fact that we have not 
explicitly modeled malaria interventions, such as bed nets or indoor residual spraying, due to the paucity of 
information on coverage by intervention type. (It is also assumed that there are no changes to the 
implementation of such interventions during the course of the trial.) It is assumed that access to treatment 
is high in the trial sites, that 90% of clinical cases receive medical care within three days of falling ill. This 
assumption is supported by the very low rates of severe malaria and malaria-attributed deaths, even in the 
control arm of the trial. Treatment rates are taken to be the same for both severe and uncomplicated 
malaria. 
 
Step 2: Fitting the properties of the initial three vaccine doses by comparing the primary clinical incidence in 
R3 and control arms of the trial. For each individual trial site, using the effective EIR determined in Step 1, 
the vaccine effect was simulated assuming a vaccine efficacy against infection described by a single 
exponential curve, parameterized by an initial (or maximum) efficacy and a half-life of protection. As for the 
fitting of the effective EIR, calendar dates of vaccine administration and site average age at first vaccination 
were used to weight simulations for alignment with true seasonal malaria exposure.  
 
Simulations were run across a range of initial efficacies and half-lives and Poisson regression was 
performed to compute the likelihood for the relationship between simulated clinical case counts and trial 
data for each efficacy-half-life combination. From these maps, the site-specific vaccine best fit was selected 
by identifying the vaccine properties that yielded the highest likelihood.  
 
Log likelihood maps for the individual trial sites were added to generate a likelihood map for the fit across 
all sites. The maximum likelihood according to this all-site likelihood map was selected to define the overall 
best fit vaccine properties. This procedure was conducted separately for the 6-12 week and 5-17 month 
trial cohorts.  
 
Step 3: Fitting the properties of the 4th dose by comparing the primary clinical incidence in R3R and R3C 
arms of the trial. The protection against infection of the 4th dose, as with the initial three vaccine doses, was 
assumed to follow a single exponential curve, though with an independent initial efficacy and half-life. The 
combined effect of the first three doses and the 4th dose is then functionally described by the sum of two 
single exponentials. 
 
For each site, simulations were run assuming the site-specific effective EIR and site-specific best fit vaccine 
properties for the first three doses, across a range of initial efficacies and half-lives for the 4th dose. 
Likelihood maps were computed for the individual sites, from which the site-specific best fit 4th dose 
properties were identified. The logs of the individual maps were added to produce the all-site likelihood map 
from which the best fit 4th dose properties were selected. As before, the procedure was conducted 
separately for the 6-12 week and 5-17 month trial cohorts. 
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Figure S2.4 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort using best-fitted vaccine profile from EMOD DTK  
 
 
Figure S2.5 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort with boost (4
th
 dose) using best-fitted vaccine profile from EMOD DTK  
2.1.3 Imperial Summary of methods and resulting vaccine properties 
The vaccine efficacy profile of RTS,S against infection and clinical malaria was estimated in a three step 
procedure. Firstly, the dynamics of RTS,S induced anti-CSP antibody titres were captured using a model 
with a bi-phasic pattern of exponential decay. Secondly, the antibody titre at a given time was used to 
predict efficacy against infection using an estimated dose-response relationship. Thirdly, the vaccine 
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efficacy against infection was related to efficacy against clinical malaria using a previously validated model 
for the age and exposure dependent acquisition of clinical immunity. The models were fitted to data from 
both the 5 to 17 month cohort and the 6 to 12 week cohort. The model was fitted to data from all trial arms 
(C3C, R3C and R3R) simultaneously using the primary case definition of malaria under according-to-
protocol (ATP) conditions42.Here we focus on the results from the 5 to 17 month cohort.  
 
Following vaccination with RTS,S, anti-CSP antibody titres are assumed to increase to CSPpeak and then 
decay over time t according to a bi-phasic exponential model as follows: 
 
 peak peak peak( ) (1 )s lr t r tCSP t CSP e e      
 
where rs and rl are the decay rates of the short-lived and long-lived components of the antibody response, 
and ρpeak is the proportion of the antibody response that is short-lived. Following a 4
th dose at time t4thDose it 
is assumed that the rate of decay of the short-lived and long-lived components of the antibody response 
remain the same, but that the proportion of the response that is short-lived ρ4thDose changes. The antibody 
dynamics can be described by the following equation: 
 
CSP(t) =CSP
4thDose
r
4thDose
e
-r
s
t-t
4thDose( ) + (1- r
4thDose
)e
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l
t-t
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The antibody dynamics model was fitted using mixed effects methods to capture the natural variation in 
antibody dynamics between individuals whilst estimating the average value and variance of the immune 
parameters across the entire cohort of children. The model was fitted using Bayesian Monte Carlo Markov 
Chain (MCMC) methods. 
 
The change in vaccine efficacy against infection over time is assumed to be determined by the changing 
anti-CSP antibody titres. The model-predicted antibody titre at time t can be used to predict vaccine efficacy 
via a dose-response curve defined as follows: 
 
 ( )
max
1
1
1 CSP t
tV V


 
  
    
where Vmax, α and β are parameters to be estimated.  
 
For each participant, exposure was determined using a prior EIR for each site combined with a fitted 
seasonal profile determined from the distribution of cases in the control cohort in each site over calendar 
time. Heterogeneity in exposure was captured using a Gamma distribution. The probability of clinical 
disease was then determined from the fitted antibody profile and a  model of the relationship between EIR 
and clinical disease adapted to be consistent with the transmission model described in Griffin et al12. This 
fitting stage was also undertaken in a Bayesian framework using MCMC methods. 
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Table S2.2: Imperial estimates of parameters describing the dynamics of RTS,S induced anti-CSP antibodies 
and the dose-response relationship.  
Parameter Description Prior Posterior 
ds half-life of short-lived antibodies 46.0 (44.5, 47.5) 46 (44, 47) days  
dl half-life of long-lived antibodies 572 (269, 1045) 583 (548, 622) days 
ρpeak proportion of short-lived antibodies following 
first 3 doses 
0.83 (0.63, 0.95) 0.88 (0.87, 0.89) 
ρboost proportion of short-lived antibodies following 
4
th
 dose  
0.83 (0.63, 0.95) 0.70 (0.68, 0.72) 
σs standard deviation in half-life of short-lived 
antibodies  
U(0, 5000) 16 (12, 25) days 
σl standard deviation in half-life of long-lived 
antibodies 
U(0, 5000) 228 (192, 271) days 
σρ,peak standard deviation in proportion short-lived 
antibodies following first 3 doses 
U(0, 5000) 0.10 (0.09, 0.11) 
σρ,4thDose standard deviation in proportion short-lived 
antibodies following 4
th
 dose 
U(0, 5000) 0.19 (0.17, 0.20) 
β dose-response scale parameter 29.1 (6.1, 82.2) 87.3 (63.3, 107.7) 
α dose-response shape parameter 0.92 (0.27, 2.19) 0.77 (0.64, 0.91) 
Vmax maximum efficacy against infection 0.91 (0.74, 0.99) 0.90 (0.81, 0.97) 
 
Priors and posteriors are presented as median and 95% credible intervals. Prior distributions were informed 
by results from Phase 2 trials of the RTS,S/AS01 and RTS,S/AS0225. U denotes a uniform distribution. 
Gamma priors were assumed for ds, dl, β and α. Beta priors were assumed for ρpeak, ρ4thDose and Vmax. Note 
that the mean and median of a distribution are not necessarily equal. 
 
 
Figure S2.6 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort using best-fitted vaccine profile from Imperial 
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Figure S2.7 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort with boost (4
th
 dose) using best-fitted vaccine profile from Imperial 
2.1.4 OpenMalaria Summary of methods and resulting vaccine properties 
The vaccine efficacy against infection profile of RTS,S was estimated as previously done for analysis of the 
18 month follow-up of the Phase III trial43. Each arm of the trial (boost, non-boosting and control for the 5-
17 month cohort) was explicitly simulated as an ensemble of 6 models18. Using Bayesian MCMC methods, 
comparing simulated incidence and Phase III trial incidences, the efficacy profile (initial efficacy against 
infection following the primary schedule of three doses, half-life of decay of efficacy against infection, shape 
parameters describing the waning profile, and efficacy against infection following a boosting dose, for each 
cohort was determined. Models were simultaneously fit to the control and vaccinated incidence from each 
trial site for the primary case definition using aggregated intention-to-treat (ITT). 
 
OpenMalaria allows different rates of decay44 in underlying efficacy against infection. For this work waning 
of the efficacy was described by a Weibull decay function curve described by the initial value of the efficacy 
𝜀0, the half-life 𝐿, and a shape parameter, 𝑘. The Weibull decay function 
takes the form 
𝜀(𝑡) = 𝜀0𝑒𝑥𝑝 (
−(𝑙𝑜𝑔2)1/𝑘𝑡
𝐿𝑘
), 
 
where 𝜀(𝑡) is the efficacy against infection at time 𝑡. When 𝑘 = 1, an exponential decay of efficacy against 
infection is obtained. If k is less than 1, the initial decay is faster than exponential and then slower than 
exponential after the time equivalent to half-life is reached, this is similar to a bi-phasic like decay, with a 
sharp decline (quick decay) in efficacy followed by longer decay. For 𝑘 greater than 1 we observe slow 
decay of efficacy against infection until the time equivalent to half-life 𝐿, and then a much faster decay. 
 
The fitting was implemented as follows: 
 
Step 1: Exposure as a distribution of Entomological Inoculation Rates (EIR) in each trial site was 
determined using the corresponding control incidence at 3 monthly time points, prevalence in 2-10 year 
olds recorded at baseline and distribution of prevalences in 2-10 years olds obtained from the MAP 2010. 
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This distribution of EIR is the EIR profiles that results in predicted prevalences that match the MAP 2010 
prevalences with access to treatment in that geographic area imputed from DHS).  For fitting, prevalences 
were scaled to match those observed in the trial sites, namely those correspond to observed high levels of 
treatment, high LLIN usage, and low severe case incidence. Site distributions of EIR assume current 
intervention coverage is static and at the level observed in the trial site. 
 
Step 2: A database of simulations from Open Malaria was created, that made both baseline and vaccine 
impact predictions over a range of EIR, levels of effective case management, and for many hypothetical 
vaccine efficacy profiles. One database was constructed for each of 6-12 weeks cohorts without and with 
the 4th dose, 5-17 month cohorts without and with the 4th dose, and the no-vaccine cohort. 
 
Step 3: Using Bayesian MCMC the vaccine efficacy profiles were determined by simultaneously fitting to 
each trial site observed vaccine incidence and control incidence for that cohort. Case management was 
allowed to vary to reflect high levels of treatment. Resulting posterior distributions of initial efficacy, half-life 
and Weibull decay function shape parameter were obtained. 
 
Step 4: The 4th dose efficacy was obtained assuming the same waning profile as the primary course. It 
was estimated by simultaneously fitting to each trial site observed vaccine incidence in the R3R and C3C 
cohorts via Bayesian MCMC.  
 
Key results are presented in Table S2.1. For the 5-17 month cohort the fitted vaccine profile was one of high 
initial efficacy against infection (91%), with a biphasic like decay (shape parameter k =0.69), with half-life 
approximately 7.3 months and when a 4th dose included the initial efficacy was approximately 50%.  
 
Predicted clinical efficacy (which was not the data used for fitting) by trial site are shown in Figures S2.8 
and S2.9.  
 
 
Figure S2.8 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort using best-fitted vaccine profile from OpenMalaria  
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Figure S2.9 Predicted efficacy against clinical disease by trial site compared to Phase III reported for the 5-17 
month cohort with boost (4
th
 dose) using best-fitted vaccine profile from OpenMalaria. 
  
33 
 
3 Cost estimates for economic analysis of RTS,S  
3.1 Program costs 
Costs of vaccine introduction are calculated from the provider perspective and are limited to cost of 
consumables including vaccines, injection and reconstitution syringes, safety box; where appropriate, 
prices are scaled up to account for freight and wastage. 
 
We opt for the limited scope of costing for the transmission scenario analysis to avoid misinterpretation of 
estimates (heterogeneity in cost of service delivery across countries and transmission intensities); the 
assumption is justified by previous analyses that showed program costs to be a minor driver of cost-
effectiveness estimates for a malaria vaccine deployed routinely45,46. The same unit cost is used across 
transmission profiles and deployment modalities. Costs are reported in 2013 USD. See Table S3.1 for unit 
prices, quantities, and data sources. Cost per dose is shown under alternate vaccine price assumptions in 
Table S3.2. As such there is no difference between the cost per visit for a routine schedule (e.g. 6 month 
and 9 months) and for those outside a routine schedule. 
 
We assumed no drop-off between doses at 90% coverage in the simulated cohort of infants. Thus the 
number of vaccines is estimated by multiplying the immunized cohort times 3. We assumed a 20 
percentage point drop-off for the 4th dose; for this modality number of vaccines is calculated as above for 
the first 3 doses plus 80% of the immunized cohort for 4th dose.  
 
Total program costs are calculated by multiplying the number of vaccines times the unit cost. 
 
Table S3.1: Prices, quantities, and unit costs for calculating cost of vaccine introduction  
Input Price Quantity Unit 
cost 
Source Notes 
Vaccine $5 1 $5 Assumption $2, $10 per dose used in sensitivity analysis 
Wastage 10%  $0.56 
45
  
Freight and 
insurance 
15%  $0.83 
45
 Applied to vaccine price including wastage 
Injection 
syringe 
(0.05ml) 
$0.05 1 $0.05 
46
 -Median supplier price;  
-Freight included in cost of goods cited by 
the UNICEF PSQ 
Reconstitution 
syringe (2ml) 
$0.03 2 $0.06 
46
 -Median supplier price;  
-Freight included in cost of goods cited by 
the UNICEF SPQ 
Wastage 10%  $0.01 
45
  
Safety box $0.60 0.01 $0.01 
46
 -Median supplier price;  
-100 syringes capacity; 
-Freight included in cost of goods cited by 
the UNICEF SPQ 
Wastage 50%  $0.01 
45
  
Total per dose   $6.52   
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Table S3.2: Cost per dose administered by vaccine price. Costs capture vaccine and related commodities. 
 
 
3.2 Treatment health savings 
Costs of malaria case management are calculated from the provider perspective and are limited to cost of 
diagnostics, antimalarial drugs, and related consumables including syringes, etc.; where appropriate prices 
are scaled up to account for freight and wastage. Costs of drugs are estimated based on the recommended 
age dosage and severity of illness. Full compliance with the recommended treatment of malaria, adherence 
with the drug regimens, and optimal cure rates are assumed for all treatments. Costs are reported in 2013 
USD. See Tables S3.3 and S3.4 for unit prices, quantities, and data sources for uncomplicated and severe 
episodes respectively. Cost of malaria case management by outcome are summarized in Table S3.5. 
Treatment health savings are estimated by multiplying cost per case averted within each age group times 
the respective cost per dose. 
3.3 Incremental cost-effectiveness ratios 
For each deployment modality the incremental cost-effectiveness ratios (ICER) are calculated relative to 
the baseline case management and for 4th dose implementation additionally relative to the 3-dose 
schedule. The ratio relates cumulative discounted program costs(3% discounting) net of any health savings 
realized by the vaccine introduction to the change in health; the latter is expressed in terms of a range of 
outcomes including DALYs, deaths, episodes, etc. ICERs are reported with and without discounting of 
benefits at 3%.  
 
Table S3.3: Prices, quantities, and unit costs for calculating cost of uncomplicated malaria episodes  
Input Price Quantity Unit cost Source Notes 
RDT $0.60 1 $0.60 
46
  
Wastage 10%  $0.06 Assumption  
ALU 
(20mg+120mg, 
tablet) 
$0.06 12 $0.72 
46
 -Dosage based on weight/age, 
see Appendix2; 
- Quantity shown for 5 year old, 
full course; adjust by age group 
Wastage 10%  $0.08 Assumption  
Total per case   $1.47   
  
Vaccine price per dose Unit cost 
$5 $6.52 
$2 $2.69 
$10 $12.91 
35 
 
Table S3.4: Prices, quantities, and unit costs for calculating cost of severe malaria episodes 
Input Price Quantity Unit cost Source Notes 
RDT $0.60 1 $0.60 
46
 -Pre-referral testing 
IV Artesunate 
(60mg, vial) 
$1.83 3 $5.49 
46
 -3 days for recovery, 2 days for death, 
7 days for neurological sequilae 
-Dosage age/ weight specific ( see 
Appendix2) 
-Quantity shown for 5 year old; adjust 
by age group 
Injection syringe 
(10 ml) 
$0.06 3 $0.18 
46
  
Reconstitution 
syringe (10 ml) 
$0.06 6 $0.36 
46
 -1 for reconstitution, 1 for dilution 
Dextrose (5%) and 
Isotonic Saline 
(0.9%) (1000ml, 
bottle) 
$1.88 2 $3.76 
46
 -Assuming fluids are needed for the 
first 2 days 
-Dosage age/ weight specific ( see 
Appendix2) 
- Quantity shown for 5 year old; adjust 
by age group 
Cannula $0.15 1 $0.15 
46
 1 per hospitalization 
IV set $1.73 2 $3.46 
46
 -1 per hospitalization 
-Assuming fluids are needed for the 
first 2 days 
Transfusion set $0.33 0.1 $0.03 
46
 -1 per hospitalization -Assigned 
proportionally with prevalence of 
severe anaemia; assume 10% of 
severe cases 
ALU (20mg+120mg, 
tablet) 
$0.06 12 $0.72 
46
 -Dosage age/ weight specific ( see 
Appendix2) 
-Quantity shown for 5 year old, full 
course; adjust by age group 
Paracetamol 
(100mg, tablet) 
$.01 10 $0.10 
46
 -Dosage age/ weight specific ( see 
Appendix2) 
- Quantity shown for 5 year old; adjust 
by age group 
Diazepam (5mg) $0.01 0.3 $0.00 
46
  -Dosage age/ weight specific ( see 
Appendix2) 
-Age/weight dose scaled by 
probability of convulsions (30%) 
- Quantity shown for 5 year old, full 
course; adjust by age group 
Amoxicillin (250mg, 
tablet) 
$0.02 21 $0.42 
46
 -Dosage age/ weight specific ( see 
Appendix2) 
- Quantity shown for 5 year old, full 
course; adjust by age group 
Wastage 10%  $1.63 Assumpti
on 
 
Microscopy $1.5 4 $6.0 Review Daily 
Safety box $0.60 0.09 $0.05 
46
  
Wastage 50%  $0.05 
45
  
Cost per severe 
case 
  $22.41   
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Table S3.5: Cost of malaria case management by age group and severity of illness (USD, 2013). Malaria case 
management costs cover antimalarials and related medication and supplies, including freight and wastage. 
  Cost per severe case by outcome 
Age Group Cost per 
uncomplicated 
case 
Recovery Neurological 
Sequilae 
Death Any 
outcome 
0-1  $1.07 $22.13 $31.20 $16.46 $21.78 
1-2  $1.07 $22.28 $31.36 $16.61 $21.93 
2-3  $1.07 $23.71 $32.79 $17.82 $23.35 
3-4  $1.47 $24.19 $33.26 $17.90 $23.79 
4-5  $1.47 $24.41 $33.49 $18.12 $24.02 
5-10  $1.47 $28.82 $37.90 $22.53 $28.43 
10-12  $1.87 $35.93 $53.14 $27.09 $35.43 
12-16 $2.27 $43.80 $61.01 $34.45 $43.26 
16-20  $2.27 $50.43 $75.77 $39.05 $49.82 
20-100  $2.27 $56.53 $90.00 $43.11 $55.85 
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4 Additional vaccine public health impact and cost-effectiveness 
results 
 
Here we include additional outputs to support predictions described in the main manuscript. 
4.1 DALY calculations 
Disability adjusted life years (DALYs) were calculated based on the duration of disability and respective 
disability weights. Weights by disease outcome and treatment have been obtained from the Global Burden 
of Disease study47. Life-time disability is assumed for severe episodes that result in neurological sequelae. 
Years of life lost (YLLs) and DALYs were calculated assuming age-specific life expectancies, based on the 
life-table from Butajira, Ethiopia, with an average life expectancy at birth of 46.6 years48. YLLs and DALYs 
were estimated based on a comprehensive measure of deaths that includes both direct malaria deaths and 
deaths due to malaria co-morbidities. For comparison, estimates based on direct malaria deaths only are 
also reported. In the light of the recent revised recommendations49 DALYs are presented without age-
weighting and discounting. For comparison with previous estimates and given lack of a general consensus 
in the literature we also report DALYs based on discounted health benefits at 3% in the Appendix tables. 
4.2 Additional Results 
4.2.1 Vaccine public health impact 
Cumulative impact of RTS,S is reported at year 15 after the vaccine introduction and is summarized in 
terms of clinical malaria cases, severe cases, hospitalised cases, deaths, and DALYs. Age specific 
estimates are provided in Figures S4.1 to S4.4 for both 3 and 4-dose schedules. Furthermore, age 
aggregated illustrations of the predicted number of events averted by the RTS,S per 100,000 fully 
vaccinated children are shown in Figure S4.5 for the schedule with a 4th dose (without 4th dose not shown). 
 
For PfPR2-10 below 10%, a positive impact was predicted by all models, however, at 3% PfPR2-10 the 
uncertainty intervals include zero (Tables S4.1- S4.2). There is more divergence in median predictions 
between the models in low (PfPR2-10 < 10%) compared to higher transmission settings (PfPR2-10 of 10% to 
65%), however, confidence intervals overlap. For PfPR2-10 above 3% up to 10% the impact is positive. At 
PfPR2-10 of 5%, the models estimate 129 (74-178) deaths are averted for every 100,000 fully vaccinated via 
the 6-9 month schedule and 144 (102-249) deaths are averted for every 100,000 fully vaccinated with the 
6-9 month schedule with a 4th dose. This averts 21% (8-25%) of malaria deaths in children under five via 
the 6-9 month schedule and 28% (9-31%) of malaria deaths in children under five via a 4-dose schedule. 
The same numbers for PfPR2-10 of 7.5%, are 187.5 (106-251) deaths are averted for every 100,000 fully 
vaccinated via the 6-9 month schedule and 224 (147-305) deaths are averted for every 100,000 fully 
vaccinated with the 6-9 month schedule with a 4th dose. This averts 19.9% (8.6-21.9) of malaria deaths in 
children under five via the 6-9 month schedule and 26.15% (9.1-27.8%) of malaria deaths in children under 
five via a 4-dose schedule. 
 
Partially protective malaria interventions reduce an individual’s exposure to malaria infection and the 
subsequent effect is to delay acquisition of natural immunity in those individuals compared to non-
intervened23,50. A delay of blood-stage immunity acquisition is predicted and observed to result in a shift of 
clinical and severe disease to older ages23,50-53. Exposure to malaria infection at older ages leads to higher 
rates of disease in all models in individuals newly exposed compared to those individuals experiencing the 
same force of infection earlier in life. This has been observed in numerous trials and investigated in settings 
with patterns of decreasing transmission during interventions; with the age-shift either reduced or 
prevented23,50,53. This age-shift is more dramatic in higher prevalence settings where natural immunity is 
acquired more rapidly. Combining this effect with the estimated biological waning of the vaccine, and 
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assuming force of infection within the population remains at the same levels over time, means that some of 
the initial impact of the vaccine on the cases averted in very young children is predicted to be offset by 
higher relative incidence at older ages (Figure S1.1 and Figures S4.1-S4.4), with this effect predicted to be 
delayed by a schedule which includes a 4th dose. Similar effects are also predicted for severe disease, with 
the age-shift occurring earlier than for clinical cases (Figures S4.1-S4.4), and predicted in the Phase III trial 
for the 3-dose schedule54.  
 
The absolute burden of the disease prevented through routine use of RTS,S is predicted to increase up to 
PfPR2-10 of 50-65%. At higher prevalence, while the predictions of the models diverge, the absolute impact 
either reaches a plateau or decreases (Figure S4.5); the greatest decrease in impact is predicted by 
OpenMalaria.  
 
Variation in predictions should be interpreted in the context of differences between the models. In 
particular, GSK and EMOD DTK differ from the OpenMalaria and Imperial in not including of the potential 
indirect (herd) effects of vaccination. Furthermore, the different mechanisms that the models use to 
translate efficacy against infection into efficacy against clinical disease contribute to variation in predictions. 
4.2.2 Cost effectiveness 
Incremental cost-effectiveness ratios (ICERs) estimated using cumulative outcomes at year 15 of the 
program for 3- and 4-dose deployments are shown in Figure 4 in the main text. These data are summarized 
in tabular form in Table S4.3 and Table S4.5. The estimates are also represented as slopes on incremental 
cost-effectiveness planes for the 5 transmission intensity settings assuming vaccine cost per dose of either 
USD$2, 5 or 10 in Figure S4.6. 
 
The ICERs for the simulated vaccination programs are generally in good agreement between the four 
models; lowest cost-effectiveness ratios are predicted by GSK and highest by EMOD DTK . For all models 
the lowest ICER is predicted at intermediate levels of transmission (PfPR2-10 of 30-50%) predicted $43-100 
per DALY averted assuming a price of $5 per dose (or US$18-45 per DALY averted assuming $2 per 
dose). The predicted incremental benefit of adding a 4th dose to the primary schedule differs between the 
models, with OpenMalaria predicting a minimal additional benefit for the 4th dose (related to boosting 
efficacy against infection profiles). Consequently, while GSK, Imperial, and EMOD DTK all predict 
somewhat more favourable cost-effective ratios for a 4th dose, predictions by OpenMalaria suggest that the 
added benefit is offset by the higher cost of the program implementation. 
 
For PfPR2-10 below 10% there is less agreement between the models, with at one extreme Imperial 
predicting small increases to the ICERs, compared to predicted large increase in ICERs by EMOD DTK. 
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Table S4.1: Deaths averted per 100,000 fully vaccinated and percentage of under 5 deaths averted by RTS,S for 6-9 month immunization schedule 
with or without 4
th
 dose at 15 years follow-up for representative parasite prevalence settings (PfPR2-10). Estimates are medians and 95% prediction 
interval for each model. 
 PfPR2-10 = 3% PfPR2-10 = 10% PfPR2-10 = 30% PfPR2-10 = 50% PfPR2-10 = 65% 
Deaths averted per 100,000 fully vaccinated by 6-9 month immunization schedule 
EMOD DTK 43 (26 to 71) 127 (79 to 194) 287 (111 to 561) 473 (187 to 708) 685 (357 to 1052) 
GSK 63 (-5 to 134) 210 (77 to 339) 570 (347 to 802) 708 (338 to 1055) - 
Imperial 136 (9 to 267) 251 (132 to 394) 391 (222 to 594) 429 (226 to 748) 397 (105 to 862) 
OpenMalaria 66 (17 to 150) 200 (97 to 300) 394 (258 to 580) 496 (328 to 682) 350 (207 to 550) 
Percentage of malaria deaths averted in children younger than 5 years by 6-9 month immunization schedule 
EMOD DTK 23.8 (13.5 to 30.5) 20.9 (16.4 to 25) 17.7 (10.3 to 27.2) 16.6 (10.4 to 21.6) 16 (9.8 to 19.8) 
GSK 24.3 (-5.3 to 45.3) 21.4 (11.8 to 32.3) 15.5 (10.6 to 20.2) 13.8 (8.9 to 18.7) - 
Imperial 22.3 (8.7 to 26.4) 18.1 (14.9 to 22.2) 13.7 (10.9 to 17.8) 11.1 (7.7 to 15.7) 9.9 (4.4 to 15.9) 
OpenMalaria 7.8 (4.1 to 14.4) 9.8 (6.8 to 12.9) 10.8 (8.6 to 13) 9 (7.3 to 10.6) 5.3 (4.3 to 7.6) 
Deaths averted per 100,000 fully vaccinated by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 61 (39 to 83) 189 (142 to 284) 406 (205 to 643) 554 (333 to 828) 838 (454 to 1180) 
GSK 81 (28 to 150) 254 (139 to 383) 715 (503 to 953) 859 (571 to 1197) - 
Imperial 184 (46 to 368) 344 (182 to 539) 501 (294 to 749) 528 (293 to 922) 484 (144 to 991) 
OpenMalaria 61 (25 to 144) 205 (118 to 316) 417 (308 to 562) 540 (326 to 663) 376 (223 to 553) 
Percentage of malaria deaths averted in children younger than 5 years by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 29.7 (23.2 to 35.9) 29.1 (25.1 to 32.8) 26.3 (19.6 to 33) 20.2 (16.1 to 27.3) 19.5 (12.4 to 24) 
GSK 33.3 (11.5 to 47) 26.7 (16.4 to 34.7) 20.7 (16.1 to 24.7) 18 (12.7 to 22.4) - 
Imperial 28.7 (17.4 to 33.7) 23.5 (20.1 to 27.4) 17.5 (14 to 22) 14 (10.4 to 18.9) 12.2 (6.4 to 18.1) 
OpenMalaria 8.9 (5.3 to 14.3) 10.3 (7.5 to 13.3) 11.4 (9.5 to 13.3) 9.7 (7.4 to 10.6) 6 (4.6 to 7.6) 
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Table S4.2: Clinical cases averted per 100,000 fully vaccinated and proportion of clinical cases averted by RTS,S for 6-9 month immunization 
schedule with or without 4
th
 dose at 15 years follow-up for representative transmission settings (PfPR2-10). Estimates are medians and 95% prediction 
interval for each model. 
 PfPR2-10 = 3% PfPR2-10 = 10% PfPR2-10 = 30% PfPR2-10 = 50% PfPR2-10 = 65% 
Clinical cases averted per 100,000 fully vaccinated by 6-9 month immunization schedule 
EMOD DTK 5771 (5180 to 6096) 20491 (19936 to 21428) 61553 (56026 to 66316) 93938 (86001 to 102252) 98877 (89804 to 114327) 
GSK 6744 (5570 to 7989) 27877 (25618 to 30284) 106031 (95597 to 115489) 126545 (105380 to 
144657) 
- 
Imperial* 14944 (-16912 to 31958) 39446 (23064 to 77032) 84590 (51532 to 126304) 114655 (71191 to 164880) 120178 (74129 to 181458) 
OpenMalaria 14889 (13860 to 15791) 47542 (43628 to 49806) 107702 (96618 to 112579) 116689 (101692 to 
130131) 
50705 (13036 to 72007) 
Proportion of clinical cases averted in under five year olds by 6-9 month immunization schedule 
EMOD DTK 20.4% (19.5 to 21.3) 19.7% (19.2 to 20.3) 18.6% (17.6 to 19.5) 16.4% (15.7 to 16.8) 13.4% (12.7 to 13.9) 
GSK 26.6% (23.2 to 30) 24.1% (22.4 to 25.7) 20% (18.9 to 20.8) 16.2% (15 to 17.4) - 
Imperial 23.8% (9 to 28.3) 21.7% (18.5 to 25.9) 18.7% (16 to 23.2) 15.8% (13.3 to 19.8) 13.5% (11 to 18.1) 
OpenMalaria 15.9% (15.5 to 16.2) 15.6% (15.1 to 15.8) 14.1% (13.6 to 14.2) 11.9% (11.1 to 12.1) 7.3% (4.8 to 8.3) 
Clinical cases averted per 100,000 fully vaccinated by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 8769 (8227 to 9228) 31448 (30478 to 32257) 93609 (88791 to 97926) 134415 (127719 to 151866) 139374 (122550 to 159521) 
GSK 8579 (7540 to 9446) 35143 (32621 to 37762) 134974 (124847 to 142563) 160411 (141739 to 179734) - 
Imperial* 21455 (-8358 to 46127) 55760 (32647 to 98616) 116482 (73731 to 166219) 154606 (96978 to 210814) 160236 (102561 to 231577) 
OpenMalaria 14659 (13664 to 15418) 46978 (43285 to 48971) 108824 (96821 to 113330) 121182 (104238 to 133815) 55849 (15613 to 77045) 
Proportion of clinical cases averted in under five year olds by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 29.2% (28.5 to 30.3) 28.4% (28 to 28.9) 27% (26 to 28) 23.3% (22.8 to 23.9) 18.5% (18 to 19.2) 
GSK 33.5% (30.5 to 35.9) 30.6% (29.2 to 31.9) 25.7% (24.9 to 26.7) 21.1% (20.1 to 22.5) - 
Imperial 30.7% (18.1 to 35.5) 28.1% (24.6 to 32) 24.4% (21.5 to 29.2) 20.6% (18 to 24.2) 17.8% (15.3 to 22.3) 
OpenMalaria 16.7% (16.2 to 16.9) 16.4% (15.9 to 16.6) 14.9% (14.3 to 15) 12.6% (11.8 to 12.9) 7.9% (5.3 to 8.9) 
*Negative cases averted at low transmission are due to stochastic variation between model runs at low prevalence rather than due to any 
modelled biological mechanism. 
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Table S4.3: Cost per DALY averted by RTS,S for 6-9 month immunization schedule with or without 4
th
 dose at 15 years follow-up for representative 
parasite prevalence settings (PfPR2-10). Estimates are medians and 95% prediction interval for each model. 
 
 PfPR2-10 = 3% PfPR2-10 = 10% PfPR2-10 = 30% PfPR2-10 = 50% PfPR2-10 = 65% 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($2 a dose) 
EMOD DTK $312 ($193 to 475) $112 ($73 to 161) $29 ($16 to 57) $21 ($13 to 32) $16 ($9 to 25) 
GSK $157 ($-2067 to 1199) $54 ($33 to 371) $19 ($13 to 33) $18 ($11 to 62) - 
Imperial $87 ($-48 to 211) $55 ($34 to 102) $43 ($27 to 78) $45 ($24 to 89) $50 ($21 to 185) 
OpenMalaria $181 ($76 to 31347) $58 ($33 to 177) $28 ($19 to 46) $24 ($16 to 42) $35 ($22 to 80) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($5 a dose) 
EMOD DTK $763 ($471 to 1159) $279 ($183 to 399) $77 ($42 to 148) $56 ($37 to 86) $44 ($26 to 67) 
GSK $383 ($-5038 to 2925) $134 ($82 to 919) $51 ($34 to 88) $49 ($30 to 161) - 
Imperial $205 ($-107 to 480) $117 ($74 to 222) $82 ($54 to 147) $80 ($45 to 155) $89 ($40 to 336) 
OpenMalaria $439 ($184 to 75820) $144 ($80 to 433) $71 ($49 to 114) $59 ($39 to 103) $84 ($53 to 190) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($10 a dose) 
EMOD DTK $1514 ($936 to 2300) $556 ($366 to 795) $155 ($86 to 302) $114 ($77 to 176) $90 ($53 to 136) 
GSK $761 ($-9989 to 5801) $269 ($165 to 1833) $105 ($70 to 178) $99 ($62 to 324) - 
Imperial $402 ($-205 to 932) $219 ($139 to 419) $147 ($97 to 261) $139 ($79 to 265) $154 ($70 to 588) 
OpenMalaria $867 ($364 to 149941) $286 ($160 to 860) $142 ($97 to 228) $118 ($77 to 206) $166 ($105 to 372) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($2 a dose) 
EMOD DTK $298 ($213 to 463) $97 ($66 to 132) $36 ($21 to 57) $26 ($17 to 41) $18 ($12 to 32) 
GSK $148 ($77 to 591) $53 ($34 to 110) $18 ($13 to 27) $18 ($12 to 32) - 
Imperial $83 ($34 to 187) $48 ($31 to 88) $38 ($25 to 69) $40 ($22 to 73) $47 ($21 to 146) 
OpenMalaria $250 ($94 to 1491) $75 ($45 to 132) $35 ($23 to 53) $28 ($22 to 51) $42 ($27 to 82) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($5 a dose) 
EMOD DTK $728 ($522 to 1130) $244 ($166 to 328) $96 ($56 to 149) $71 ($46 to 110) $48 ($35 to 85) 
GSK $362 ($190 to 1443) $133 ($86 to 273) $49 ($34 to 72) $49 ($33 to 83) - 
Imperial $195 ($80 to 440) $105 ($68 to 195) $77 ($50 to 133) $76 ($43 to 136) $87 ($41 to 278) 
OpenMalaria $602 ($227 to 3596) $183 ($111 to 323) $87 ($57 to 131) $69 ($54 to 126) $101 ($66 to 195) 
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Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($10 a dose) 
EMOD DTK $1447 ($1037 to 2243) $487 ($332 to 657) $197 ($116 to 303) $146 ($96 to 224) $99 ($73 to 173) 
GSK $720 ($377 to 2862) $267 ($172 to 546) $100 ($70 to 147) $100 ($66 to 168) - 
Imperial $382 ($158 to 861) $200 ($128 to 374) $141 ($93 to 241) $137 ($78 to 245) $154 ($74 to 500) 
OpenMalaria $1189 ($448 to 7105) $363 ($221 to 640) $174 ($114 to 261) $138 ($107 to 251) $199 ($131 to 383) 
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Table S4.4: Deaths averted per 100,000 fully vaccinated and percentage of under 5 deaths averted by RTS,S for 6-9 month immunization schedule 
with or without 4
th
 dose at 15 years follow-up for low prevalence representative transmission settings (PfPR2-10). Estimates are medians and 95% 
prediction interval for each model. 
 PfPR2-10 = 3% PfPR2-10 = 5% PfPR2-10 = 7.5% PfPR2-10 = 10% PfPR2-10 = 15% 
Deaths averted per 100,000 fully vaccinated by 6-9 month immunization schedule 
EMOD DTK 43 (26 to 71) 74 (46 to 103) 106 (68 to 153) 127 (79 to 194) 160 (99 to 247) 
GSK 63 (-5 to 134) 85 (7 to 160) 141 (47 to 217) 210 (77 to 339) 390 (210 to 577) 
Imperial 136 (9 to 267) 178 (78 to 306) 225 (110 to 359) 251 (132 to 394) 306 (169 to 472) 
OpenMalaria 66 (17 to 150) 115 (29 to 259) 150 (70 to 287) 200 (97 to 300) 266 (164 to 388) 
Percentage of deaths averted in children younger than 5 years by 6-9 month immunization schedule 
EMOD DTK 23.8% (13.5 to 30.5) 21.6% (15.1 to 27.6) 20.5% (15.7 to 25.4) 20.9% (16.4 to 25) 19.8% (16.5 to 22.7) 
GSK 24.3% (-5.3 to 45.3) 27.4% (7.3 to 43.3) 21.5% (9.9 to 32.9) 21.4% (11.8 to 32.3) 16.1% (10.3 to 24) 
Imperial 22.3% (8.7 to 26.4) 20.7% (16.7 to 25.4) 19.3% (15.6 to 23.2) 18.1% (14.9 to 22.2) 16.4% (13.7 to 20.2) 
OpenMalaria 7.8% (4.1 to 14.4) 7.8% (4.1 to 14.4) 8.6% (6.8 to 13.3) 9.8% (6.8 to 12.9) 11.1% (8.1 to 13.5) 
Deaths averted per 100,000 fully vaccinated by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 61 (39 to 83) 102 (74 to 145) 151 (113 to 203) 189 (142 to 284) 250 (178 to 334) 
GSK 81 (28 to 150) 107 (49 to 172) 174 (75 to 258) 254 (139 to 383) 511 (333 to 684) 
Imperial 184 (46 to 368) 249 (114 to 430) 297 (157 to 495) 344 (182 to 539) 414 (218 to 603) 
OpenMalaria 61 (25 to 144) 106 (43 to 248) 147 (101 to 287) 205 (118 to 316) 293 (170 to 381) 
Percentage of deaths averted in children younger than 5 years by 6-9 month immunization schedule with 4
th
 dose 
EMOD DTK 29.7% (23.2 to 35.9) 29.1% (23.1 to 35.5) 27.8% (24.4 to 32.1) 29.1% (25.1 to 32.8) 28.8% (25.6 to 31) 
GSK 33.3% (11.5 to 47) 32.5% (20.4 to 48.8) 28.5% (18 to 37.3) 26.7% (16.4 to 34.7) 22.1% (14.2 to 26.9) 
Imperial 28.7% (17.4 to 33.7) 27% (22.8 to 32.5) 25% (21.2 to 28.8) 23.5% (20.1 to 27.4) 21.4% (18.4 to 25.2) 
OpenMalaria 8.9% (5.3 to 14.3) 8.9% (5.3 to 14.3) 9.1% (7.6 to 13.1) 10.3% (7.5 to 13.3) 11.8% (8.9 to 13.7) 
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Table S4.5:  Cost per DALY averted by RTS,S for 6-9 month immunization schedule with or without 4
th
 dose at 15 years follow-up for low 
prevalence representative transmission settings (PfPR2-10). Estimates are medians and 95% prediction interval for each model. 
 
 PfPR2-10 = 3% PfPR2-10 = 5% PfPR2-10 = 7.5% PfPR2-10 = 10% PfPR2-10 = 15% 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($2 a dose) 
EMOD DTK $312 ($193 to 475) $204 ($142 to 300) $135 ($96 to 213) $112 ($73 to 161) $89 ($58 to 139) 
GSK $157 ($-2067 to 1199) $128 ($-234 to 3530) $76 ($50 to 376) $54 ($33 to 371) $27 ($18 to 68) 
Imperial $87 ($-48 to 211) $70 ($39 to 154) $60 ($36 to 122) $55 ($34 to 102) $48 ($31 to 87) 
OpenMalaria $181 ($76 to 31347) $104 ($44 to 17867) $77 ($38 to 161) $58 ($33 to 177) $42 ($29 to 76) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($5 a dose) 
EMOD DTK $763 ($471 to 1159) $500 ($349 to 736) $334 ($237 to 523) $279 ($183 to 399) $223 ($147 to 348) 
GSK $383 ($-5038 to 2925) $314 ($-569 to 8613) $188 ($123 to 924) $134 ($82 to 919) $70 ($46 to 173) 
Imperial $205 ($-107 to 480) $159 ($88 to 344) $130 ($78 to 261) $117 ($74 to 222) $98 ($65 to 178) 
OpenMalaria $439 ($184 to 75820) $252 ($106 to 43586) $190 ($94 to 394) $144 ($80 to 433) $105 ($72 to 189) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule ($10 a dose) 
EMOD DTK $1514 ($936 to 2300) $995 ($693 to 1462) $665 ($474 to 1041) $556 ($366 to 795) $446 ($294 to 697) 
GSK $761 ($-9989 to 5801) $625 ($-1128 to 17086) $376 ($246 to 1837) $269 ($165 to 1833) $142 ($94 to 349) 
Imperial $402 ($-205 to 932) $306 ($168 to 662) $246 ($150 to 493) $219 ($139 to 419) $181 ($119 to 329) 
OpenMalaria $867 ($364 to 149941) $500 ($210 to 86451) $377 ($188 to 781) $286 ($160 to 860) $211 ($144 to 376) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($2 a dose) 
EMOD DTK $298 ($213 to 463) $188 ($133 to 262) $126 ($93 to 165) $97 ($66 to 132) $72 ($54 to 101) 
GSK $148 ($77 to 591) $116 ($75 to 364) $74 ($48 to 272) $53 ($34 to 110) $24 ($17 to 39) 
Imperial $83 ($34 to 187) $62 ($36 to 132) $53 ($32 to 105) $48 ($31 to 88) $42 ($27 to 76) 
OpenMalaria $250 ($94 to 1491) $144 ($54 to 853) $101 ($52 to 157) $75 ($45 to 132) $51 ($38 to 91) 
Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($5 a dose) 
EMOD DTK $728 ($522 to 1130) $462 ($328 to 643) $312 ($232 to 409) $244 ($166 to 328) $181 ($136 to 256) 
GSK $362 ($190 to 1443) $285 ($186 to 889) $183 ($120 to 669) $133 ($86 to 273) $63 ($45 to 100) 
Imperial $195 ($80 to 440) $143 ($84 to 305) $120 ($72 to 230) $105 ($68 to 195) $89 ($59 to 165) 
OpenMalaria $602 ($227 to 3596) $347 ($131 to 2070) $245 ($127 to 380) $183 ($111 to 323) $126 ($95 to 222) 
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Cost per DALY averted (USD$) by 6-9 month immunization schedule with 4
th
 dose ($10 a dose) 
EMOD DTK $1447 ($1037 to 2243) $919 ($654 to 1280) $622 ($463 to 815) $487 ($332 to 657) $363 ($275 to 514) 
GSK $720 ($377 to 2862) $567 ($369 to 1765) $366 ($240 to 1330) $267 ($172 to 546) $128 ($92 to 203) 
Imperial $382 ($158 to 861) $278 ($163 to 594) $232 ($139 to 439) $200 ($128 to 374) $168 ($114 to 313) 
OpenMalaria $1189 ($448 to 7105) $686 ($259 to 4099) $486 ($252 to 753) $363 ($221 to 640) $249 ($188 to 442) 
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Table S4.6: Summary predictions of public health impact and cost-effectiveness of RTS,S for 6-9 month immunization schedule with or without 4
th
 
dose at 15 years follow-up. Estimates are presented as median and ranges across the model’s medians 
Outcome Vaccination 
Schedule 
PfPR2-10  
3% to 65% 
PfPR2-10  
10% to 65% 
PfPR2-10  
10% to 50% 
PfPR2-10  
30% to 50% 
PfPR2-10  
10% 
PfPR2-10  
7·5% 
PfPR2-10  
5% 
Public Health Impact 
Proportion of 
deaths under 5 
averted 
6-9 months 
with 4
th
 dose 
19.5% (6-33.3) 18% (6-29.1) 19.1% (9.7-
29.1) 
17.8% (9.7-
26.3) 
25.1% (10.3-
29.1) 
26.4% (9.1-
28.5) 
28.1% (8.9-
32.5) 
6-9 months 15.5% (5.3-
24.3) 
13.8% (5.3-
21.4) 
14.7% (9-21.4) 13.8% (9-17.7) 19.5% (9.8-
21.4) 
19.9% (8.6-
21.5) 
21.2% (7.8-
27.4) 
Proportion of 
clinical cases 
under 5 
averted 
6-9 months 
with 4
th
 dose 
23.3% (7.9-
33.5) 
21.1% (7.9-
30.6) 
23.9% (12.6-
30.6) 
22.2% (12.6-
27) 
28.3% (16.4-
30.6) 
28.6% (16.5-
31.6) 
29.3% (16.7-
33) 
6-9 months 16.4% (7.3-
26.6) 
16.2% (7.3-
24.1) 
17.5% (11.9-
24.1) 
16.3% (11.9-
20) 
20.7% (15.6-
24.1) 
21% (15.8-
25.3) 
21.45% (15.9-
26.2) 
Deaths 
averted per 
100,000 fully 
vaccinated 
6-9 months 4
th
 
dose 
406 (61-859) 484 (189-859) 459 (189-859) 534 (406-859) 229.5 (189-
344) 
162.5 (147-
297) 
106.5 (102-
249) 
6-9 months 350 (43-708) 394 (127-708) 392.5 (127-
708) 
451 (287-708) 205 (127-251) 145.5 (106-
225) 
100 (74-178) 
Clinical cases 
averted per 
100,000 fully 
vaccinated 
6-9 months 4
th
 
dose 
93609 (8579-
160411) 
116482 
(31448-
160411) 
112653 
(31448-
160411) 
127799 
(93609-
160411) 
41060.5 
(31448-55760) 
29740.5 
(21799-46784) 
20299.5 
(11072-34063) 
6-9 months 61553 (5771-
126545) 
93938 (20491-
126545) 
89264 (20491-
126545) 
106867(61553-
126545) 
33661.5 
(20491-47542) 
24807 (14790-
37273) 
16788 (8854-
25745) 
Incremental benefit (% of additional events averted of boosting schedule compared to non-boosting) 
Incremental 
benefit 
Deaths 22% (-8-49) 22% (3-49) 22% (3-49) 22% (6-41) 20% (3-49) 28% (-2-42) 33% (-8-40) 
Clinical cases 33% (-2-53) 33% (-1-53) 31% (-1-53) 31% (1-52%) 34% (-1-53) 35% (-1-53) 34% (-2-56) 
Cost-effectiveness (ICER per DALY averted.) 
$2 a dose 6-9 months 4
th
 
dose 
$42 ($18-298) $38 ($18-97) $37 ($18-97) $31.5 ($18-40) $64 ($48-97) $87.5 ($53-
126) 
$130 ($62-188) 
6-9 months $45 ($16-312) $35 ($16-112) $36 ($18-112) $26 ($18-45) $56.5 ($54-
112) 
$76.5 ($60-
135) 
$116 ($70-204) 
$5 a dose 6-9 months 4
th
 
dose 
$96 ($48-728) $87 ($48-244) $82 ($49-244) $73.5 ($49-96) $158 ($105-
244) 
$214 ($120-
312) 
$316 ($143-
462) 
6-9 months $84 ($44-763) $80 ($44-279) $78.5 ($49-
279) 
$65 ($49-82) $139 ($117-
279) 
$189 ($130-
334) 
$283 ($159-
500) 
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$10 a dose 6-9 months 4
th
 
dose 
$197 ($99-
1447) 
$154 ($99-
487) 
$160 ($100-
487) 
$140 ($100-
197) 
$315 ($200-
487) 
$426 ($232-
622) 
$626.5 ($278-
919) 
6-9 months $155 ($90-
1514) 
$147 ($90-
556) 
$144.5 ($99-
556) 
$128.5 ($99-
155) 
$277.5 ($219-
556) 
$376.5 ($246-
665) 
$562.5 ($306-
995) 
Cost-effectiveness (ICER per clinical case averted.) 
$2 a dose 6-9 months 4
th
 
dose 
$18 ($6-115) $10 ($6-93) $13.5 ($6-33) $9.5 ($6-20) $26.5 ($18-33) $37.5 ($21-43) $61.5 ($27-68) 
6-9 months $16 ($7-138) $13 ($7-88) $13 ($7-38) $11 ($7-16) $24 ($22-38) $34 ($26-53) $58.5 ($32-81) 
$5 a dose 6-9 months 4
th
 
dose 
$42 ($16-281) $25 ($16-222) $32.5 ($16-80) $19 ($16-49) $65.5 ($40-80) $92.5 ($46-
108) 
$151 ($62-167) 
6-9 months $40 ($18-337) $30 ($18-211) $32 ($18-94) $21.5 ($18-40) $60 ($45-94) $84 ($55-131) $143 ($71-198) 
$10 a dose 6-9 months 4
th
 
dose 
$84 ($28-558) $51 ($28-437) $63 ($29-159) $36.5 ($29-97) $131 ($75-
159) 
$184 ($89-
215) 
$299.5 ($120-
333) 
6-9 months 4
th
 
dose 
$80 ($31-669) $61 ($31-415) $64 ($32-187) $41 ($32-80) $119.5 ($84-
187) 
$167 ($103-
260) 
$284.5 ($137-
394) 
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Figure S4.1: Clinical cases averted per 100,000 fully vaccinated children stratified by age group and PfPR2-10. 
Rows indicate parasite prevalence intensity, columns and colour modelling groups (green EMOD DTK, orange GSK, 
blue Imperial, purple OpenMalaria). Bars show events averted during 15 years of use of RTS,S within a 6-9 month 
immunisation schedule; black dots indicated events averted by the same schedule but administration of an additional 
4th dose at 27 months. Note the y-axis for each prevalence row are at different scales. 
 
Figure S4.2: Severe cases averted per 100,000 fully vaccinated children stratified by age group and PfPR2-10. 
Rows indicate parasite prevalence intensity, columns and colour modelling groups (green EMOD DTK, orange GSK, 
blue Imperial, purple OpenMalaria). Bars show events averted during 15 years of use of RTS,S within a 6-9 month 
immunisation schedule; black dots indicated events averted by the same schedule but administration of an additional 
4
th
 dose at 27 months. Note the y-axis for each prevalence row are at different scales. 
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Figure S4.3: Hospitalised cases averted per 100,000 fully vaccinated children stratified by age group and 
PfPR2-10. Rows indicate parasite prevalence intensity, columns and colour modelling groups (green EMOD DTK, 
orange GSK, blue Imperial, purple OpenMalaria). Bars show events averted during 15 years of use of RTS,S within a 
6-9 month immunisation schedule; black dots indicated events averted by the same schedule but administration of an 
additional 4
th
 dose at 27 months. Note the y-axis for each prevalence row are at different scales. 
 
Figure S4.4: Deaths averted per 100,000 fully vaccinated children stratified by age group and PfPR2-10. Rows 
indicate parasite prevalence intensity, columns and colour modelling groups (green EMOD DTK, orange GSK, blue 
Imperial, purple OpenMalaria). Bars show events averted during 15 years of use of RTS,S within a 6-9 month 
immunisation schedule; black dots indicated events averted by the same schedule but administration of an additional 
4
th
 dose at 27 months. Note the y-axis for each prevalence row are at different scales. 
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Figure S4.5: The cumulative number of either clinical cases, severe cases, hospitalised cases, death or 
DALYs averted per 100,000 fully vaccinated children within 15 years after the start of RTS,S vaccination in a 6 
to 9 months schedule with a 4th dose (results without 4
th
 dose not shown). 
 
Figure S4.6: Cost effective planes comparing the net program costs of RTS,S  with the DALYs averted. 
Showing total net incremental costs and DALYs averted for use of RTS,S within a 6 to 9months schedule over routine 
malaria control and incremental costs and DALYs averted of RTS,S with and without 4
th
 dose are shown for different 
transmission settings and vaccine prices. Grey reference lines represent ratios of 100, 200 and 300 USD per DALY 
averted. Colour indicates group (green EMOD DTK, orange GSK, blue Imperial, purple OpenMalaria)  
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5 Sensitivity analysis of RTS,S cost-effectiveness  
 
This section of the Appendix provides details of a sensitivity analysis of RTS,S cost-effectiveness in generic 
transmission settings. One modelling group- Swiss TPH - assessed the impact of uncertainty around the 
vaccine properties, health systems and economic parameters on the cost-effectiveness of the vaccine in a 
series of one-way sensitivity analyses. Since the costing approach was standardised across models, the 
variation in these factors is expected to be mirrored for the other models.Immunization coverage and 
access to malaria case management ranges were obtained by scaling the baseline values up and down 
25% up to the highest/ lowest values simulated. For vaccine properties best fit values were used in the 
baseline simulations, low and high posteriors were used for the upper and lower ranges. Additionally 
estimates of vaccine cost-effectiveness were produced under the worst- and best case assumptions of 
vaccine properties. Parameter values and ranges are detailed in Table S5.1.  
5.1 Harmonization assumptions  
Methodology to estimate vaccine efficacy against clinical malaria are detailed in section 2 of Supplementary 
Appendix. Predictions reported here are based on best-fit vaccine efficacy profiles as estimated by Swiss 
TPH and detailed in Figure 3 in the main text. The model is harmonized along all other inputs including 
exposure, demographics, immunization coverage, and costs (see Table 1 and sections 1, 3, 4 in 
Supplementary Appendix).  
5.2 Sensitivity analysis 
ICERs were produced for each transmission setting and vaccination schedule by varying each of the 
parameters detailed in Table S5.1 while holding all other inputs at baseline values. Sensitivity 1-6 and 8-10 
in Table S5.1 are one-way sensitivity analyses, where as sensitivity 7 is a scenario analysis on vaccine 
properties, with the worst case, and best case vaccine properties based on half-life and initial efficacy 
against infection. The direction and broad magnitude of changes in ICERs were similar for the two 
deployment modalities. For sake of brevity only estimates for 4-dose schedule are presented. Table S5.2 
presents outcomes of one-way sensitivity in terms of cost per DALY averted (cumulative ICER 15 years 
after program implementation). Figure S5.1 summarizes these results as tornado plots: the cost per DALY 
averted over the 15-year time horizon at most doubles from the baseline estimate when considering a 
range of factors including lower vaccination coverage, lower estimates of vaccine efficacy and higher 
vaccine price, with the greatest impact due to a price increase from $5 to $10. 
 
Table S5.1: List of parameters and ranges varied in one-way sensitivity analysis 
Sensitivity  Parameter Baseline Value Low Value High Value 
1 Access
a
                45% 33.75% 56.25% 
2 Immunization 
coverage 
90% 67.5% 100% 
4 Initial Efficacy against 
infection
b
 
92% 75%  99% 
5 Efficacy 4
th
 dose 49.1% 32% 69% 
6 Half-life
c
 7.32 months 6 months 10.2 months 
7 Profile
c
 Efficacy 92%, half-
life 7.32 months 
Efficacy 75%, 
half-life 6 months 
Efficacy 99%, half-
life 10.2 months 
8 Vaccine price per dose $5 $2 $10 
9 Discount rate 3% 0% 10% 
10 Horizon 15 5 10 
a 
Access refers to proportion of fevers that are treated effectively (cured parasitaemia) by the routine case 
management regardless of source of treatment. 
b
 Efficacy refers to initial efficacy against infection with lower and 
upper limits taken from the posterior distributions of initial efficacy from OpenMalaria (Table S2.1), with the lower value 
(75%) roughly representing representing 80% of baseline. 
c
 Weibull, biphasic decay.  
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Table S5.2: OpenMalaria one-way sensitivity of RTS,S cost-effectiveness as ICER per DALY averted by transmission level. The cumulative cost per 
DALY averted within 15 years after the start of vaccination with RTS,S in a 6 to 9 months schedule with a 4th dose administered 18 months after the third 
dose (USD 2013). 
  PfPR2-10= 3 PfPR2-10=10 PfPR2-10=30 PfPR2-10=50 PfPR2-10=65 
No Parameter Baseline 
Value 
Low 
Value 
High 
Value 
Baseli
ne 
Value 
Low 
Value 
High 
Value 
Baseli
ne 
Value 
Low 
Value 
High 
Value 
Baseli
ne 
Value 
Low 
Value 
High 
Value 
Baseli
ne 
Value 
Low 
Value 
High 
Value 
1 Access
a
                $602 $461 $602 $183 $141 $183 $87 $74 $87 $69 $65 $69 $101 $96 $101 
2 Immunizatio
n coverage 
$602 $602 $669 $183 $183 $203 $87 $87 $97 $69 $69 $77 $101 $101 $112 
4 Initial 
Efficacy
b
 
$602 $625 $572 $183 $221 $176 $87 $105 $82 $69 $89 $63 $101 $124 $91 
5 Efficacy 4
th
 
dose 
$602 $636 $531 $183 $207 $161 $87 $96 $78 $69 $74 $64 $101 $106 $94 
6 Half-life
c
 $602 $645 $516 $183 $196 $154 $87 $93 $74 $69 $74 $59 $101 $107 $81 
7 Profile $602 $699 $434 $183 $263 $127 $87 $123 $63 $69 $107 $50 $101 $159 $71 
8 Profile, 
coverage 
$602 $699 $483 $183 $263 $141 $87 $123 $70 $69 $107 $56 $101 $159 $79 
9 Vaccine 
price per 
dose 
$602 $250 $1'189 $183 $75 $363 $87 $35 $174 $69 $28 $138 $101 $42 $199 
10 Discount 
rate 
$602 $734 $410 $183 $223 $124 $87 $107 $60 $69 $85 $47 $101 $124 $68 
11 Horizon $602 $663 $574 $183 $197 $182 $87 $100 $90 $69 $77 $69 $101 $87 $93 
a
 Access refers to proportion of fevers that are treated effectively (cured parasitaemia) by the routine case management regardless of source of treatment. 
b
 
Efficacy refers to initial efficacy against infection. 
c
 Weibull, biphasic decay. 
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Figure S5.1: OpenMalaria one-way sensitivity and scenario analysis of RTS,S cost-effectiveness. Results show 
cost per DALY averted (USD, 2013) for 6-9 month schedule with 4 doses by transmission level (a) PfPR2-10=10%, (b) 
PfPR2-10=30%, (c) PfPR2-10=50%, (d) PfPR2-10=65%.  
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